Acumen Pharmaceuticals In... (ABOS)
Acumen Pharmaceuticals Statistics
Share Statistics
Acumen Pharmaceuticals has 60.57M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 60.57M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 70.73% |
| Shares Floating | 44.28M |
| Failed to Deliver (FTD) Shares | 264 |
| FTD / Avg. Volume | 0.11% |
Short Selling Information
The latest short interest is 1.65M, so 2.75% of the outstanding shares have been sold short.
| Short Interest | 1.65M |
| Short % of Shares Out | 2.75% |
| Short % of Float | 3.7% |
| Short Ratio (days to cover) | 6.81 |
Valuation Ratios
The PE ratio is -1.01 and the forward PE ratio is -0.6. Acumen Pharmaceuticals's PEG ratio is -0.02.
| PE Ratio | -1.01 |
| Forward PE | -0.6 |
| PS Ratio | 0 |
| Forward PS | 1.1 |
| PB Ratio | 0.57 |
| P/FCF Ratio | -1.2 |
| PEG Ratio | -0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Acumen Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.46, with a Debt / Equity ratio of 0.16.
| Current Ratio | 6.46 |
| Quick Ratio | 6.46 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | -0.29 |
| Debt / FCF | -0.33 |
| Interest Coverage | -28.03 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.68M |
| Employee Count | 61 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -67.92% in the last 52 weeks. The beta is 0.1, so Acumen Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.1 |
| 52-Week Price Change | -67.92% |
| 50-Day Moving Average | 1.2 |
| 200-Day Moving Average | 2.1 |
| Relative Strength Index (RSI) | 45.05 |
| Average Volume (20 Days) | 233.96K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -114.02M |
| Net Income | -102.33M |
| EBITDA | -98.08M |
| EBIT | -98.26M |
| Earnings Per Share (EPS) | -1.71 |
Balance Sheet
The company has 35.63M in cash and 28.73M in debt, giving a net cash position of 6.89M.
| Cash & Cash Equivalents | 35.63M |
| Total Debt | 28.73M |
| Net Cash | 6.89M |
| Retained Earnings | -325.13M |
| Total Assets | 238.99M |
| Working Capital | 150.7M |
Cash Flow
In the last 12 months, operating cash flow was -86.22M and capital expenditures -16K, giving a free cash flow of -86.23M.
| Operating Cash Flow | -86.22M |
| Capital Expenditures | -16K |
| Free Cash Flow | -86.23M |
| FCF Per Share | -1.44 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ABOS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ABOS is $7, which is 586.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 586.3% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -1.81 |
| Piotroski F-Score | 1 |